Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Silvia Armuzzi
Observed name:
S. Armuzzi
Institutions:
Istituto di Ematologia di Bologna,
University of Bologna
Observed institutions:
University Hospital Heidelberg,
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
Istituto di Ematologia di Bologna,
University of Bologna
ORCID:
0000-0001-6690-2590
Observed ORCID:
0000-0001-6690-2590
OpenAlex ID:
A5014299942
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
2022
·
M. Martello
, A. Poletti
, et al.
·
Blood Cancer Journal
·
47
PDF
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
2024
·
Marina Martello
, Vincenza Solli
, et al.
·
Blood Cancer Journal
·
24
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases
2022
·
Ilaria Vigliotta
, Silvia Armuzzi
, et al.
·
Frontiers in Oncology
·
14
PDF
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features
2024
·
Carolina Terragna
, Andrea Poletti
, et al.
·
Nature Communications
·
13
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia
2021
·
Alessandro Broccoli
, Carolina Terragna
, et al.
·
Hematological Oncology
·
13
PDF
Bispecific Antibodies and Cart in Multiple Myeloma: Appropriate Selection of Patients and Sequencing
2025
·
Michele Puppi
, Ilaria Sacchetti
, et al.
·
Mediterranean Journal of Hematology and Infectious Diseases
·
12
PDF
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients
2024
·
Enrica Borsi
, Ilaria Vigliotta
, et al.
·
Cells
·
11
PDF
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients
2024
·
Ilaria Vigliotta
, Vincenza Solli
, et al.
·
Cancers
·
9
PDF
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients
2023
·
Enrica Borsi
, Gaia Mazzocchetti
, et al.
·
Clinical and Experimental Medicine
·
7
PDF
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma
2025
·
Andrea Poletti
, Barbara Taurisano
, et al.
·
Haematologica
·
6
BoBafit : A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles
2022
·
G. Mazzocchetti
, A. Poletti
, et al.
·
Computational and Structural Biotechnology Journal
·
5
C5 and SRGAP3 Polymorphisms Are Linked to Paediatric Allergic Asthma in the Italian Population
2022
·
Daria Messelodi
, Cristina Giuliani
, et al.
·
Genes
·
3
PDF
Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real‐World Evidence in a Rapidly Evolving Therapeutic Landscape
2026
·
K. Mancuso
, S. Masci
, et al.
·
European Journal Of Haematology
·
2
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients
2022
·
Marina Martello
, Vincenza Solli
, et al.
·
International Journal of Molecular Sciences
·
2
PDF
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real‐Life Italian Multicenter Harmonization Experience
2026
·
Stefania Oliva
, Marina Martello
, et al.
·
Cancer Medicine
·
1
OAB-059: Towards a comprehensive multimodal minimal residual disease assessment in multiple myeloma: the role of circulating cell-free DNA to define the extent of disease spreading
2021
·
Marina Martello
, Andrea Poletti
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma
2019
·
Carolina Terragna
, Andrea Poletti
, et al.
·
Blood
·
1
OA-36 Longitudinal Liquid Biopsy Monitoring Reveals Distinct Residual Disease Dynamics Beyond Bone Marrow MRD Assessment in Newly Diagnosed Multiple Myeloma
2026
·
Carolina Terragna
, Vincenza Solli
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
PA-051 Beyond Consensus Genomic Staging: Genomic Heterogeneity of Relapsed Standard-Risk Multiple Myeloma
2026
·
Viola Meixian Vuong
, Vincenza Solli
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
PA-026 An Integrated High-Sensitivity Flow Cytometry Platform Revealing Dissemination-Associated Phenotypes and Therapeutic Target Heterogeneity in Multiple Myeloma: The MMulticolors Panel
2026
·
Alessia Varacalli
, Ilaria Vigliotta
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
PA-285 Longitudinal ctDNA Profiling Enables Early Detection of Relapse and Clonal Dynamics in Multiple Myeloma
2026
·
Marina Martello
, Gaia Mazzocchetti
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
LBA-26 High-Sensitivity Longitudinal Circulating Plasma Cells Monitoring After T-Cell-Redirecting Therapies: The Impact of Early Clearance on Response and Survival Outcomes
2026
·
Ilaria Vigliotta
, Alessia Varacalli
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
PA-500 TP53 Isoform Switching Defines Functional States and Clinical Risk in Multiple Myeloma
2026
·
Enrica Borsi
, Alessandra Vitale
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Circulating plasma cells (polyclonal and monoclonal) as markers of an aggressive multiple myeloma phenotype
2026
·
Ilaria Vigliotta
, Alessia Varacalli
, et al.
·
Scientific Reports
PDF
Comparative Analysis Between the EuroClonality-NGS Approach and the LymphoTrack® Dx Assay for IG/TR Marker Screening in Lymphoid Leukemias: A Campus ALL Study
2026
·
Irene Della Starza
, Vittorio Bellomarino
, et al.
·
International Journal of Molecular Sciences
Show more works
View as search
Works count:
45
Citation count:
171
H-index:
8
I10-index:
7
Year
Topic
Type